【摘要】 目的评价雷替曲塞联合洛铂方案在原发性肝癌患者应用肝动脉灌注化疗栓塞(transcatheter arterial chemoembolization,TACE)中的价值及意义。方法选择TACE治疗的原发性肝癌患者,分为观察组(n=53)给予雷替曲塞联合洛铂灌注化疗,对照组(n=50)给予替加氟联合洛铂行TACE治疗,术后4周以改良的实体瘤疗效评价标准评估疗效,随访时间截至2018年10月30日。结果随访观察观察组和对照组中位无进展生存期分别为14.8个月和11.2个月,差异有统计学意义(P<0.05);中位总生存期分别为23.7个月及21.6个月,差异无统计学意义(P>0.05);疾病有效率分别为47.1%、46.0%,差异无统计学意义(P>0.05);疾病控制率分别为88.7%、62.0%,差异有统计学意义(P<0.05)。结论雷替曲塞联合洛铂灌注化疗方案在肝癌TACE治疗中可提高患者预后,值得深入探讨。更多还原

【Abstract】 Objective To evaluate the clinical value of the combination regimen of retitroxel and lobaplatin in transcatheter arterial chemoembolization(TACE) for patients with primary hepatocellular carcinoma(PHC). Methods Patients with primary liver cancer who received TACE treatment were divided into two groups: observation group(n=53) and control group(n=50), which received TACE treatment combined with Rigtroxel and Loplatin. The efficacy was evaluated by Modified Response Evaluation Criteria in Solid Tumors standard 4 weeks after operation. The last follow-up period was October 30, 2018. Results The median progression-free survival(mPFS) was 14.8 months in the treatment group and 11.2 months in the control group, with significant difference(P<0.05). The median overall survival time was 23.7 months and 21.6 months, respectively, with no significant difference(P>0.05). The disease effective rate(ORR) was 47.1% and 46.0%, respectively, with no significant difference(P>0.05). The disease control rate(DCR) was 88.7% and 62.0%, respectively, with significant difference(P<0.05). Conclusion Retitroxel combined with Loplatin is a valuable perfusion chemotherapy regimen in TACE treatment, which deserves further discussion.更多还原